Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment

References

• Amaral TM, Macedo D, Fernandes I, Costa L. Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate Cancer 2012; 2012:327253; http://dx.doi.org/10.1155/2012/327253; PMID: 22530130
   PubMedGoogle Scholar
• Hoffman-Censits J, Kelly WK. Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer. Clin Cancer Res 2013; 19:1335 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-12-2910; PMID: 23300275
   PubMed Web of Science ®Google Scholar
• Michielsen DP, Braeckman JG, Denis L. Cabazitaxel for the treatment of prostate cancer. Expert Opin Pharmacother 2011; 12:977 - 82; http://dx.doi.org/10.1517/14656566.2011.567268; PMID: 21406025
   PubMed Web of Science ®Google Scholar
• El-Amm J, Aragon-Ching JB. The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol 2013; 5:25 - 40; http://dx.doi.org/10.1177/1758834012458137; PMID: 23323145
   PubMed Web of Science ®Google Scholar
• Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1:34 - 45; http://dx.doi.org/10.1038/35094009; PMID: 11900250
   PubMed Web of Science ®Google Scholar
• Anazawa Y, Nakagawa H, Furihara M, Ashida S, Tamura K, Yoshioka H, Shuin T, Fujioka T, Katagiri T, Nakamura Y. PCOTH, a novel gene overexpressed in prostate cancers, promotes prostate cancer cell growth through phosphorylation of oncoprotein TAF-Ibeta/SET. Cancer Res 2005; 65:4578 - 86; http://dx.doi.org/10.1158/0008-5472.CAN-04-4564; PMID: 15930275
   PubMed Web of Science ®Google Scholar
• Isaacs W, De Marzo A, Nelson WG. Focus on prostate cancer. Cancer Cell 2002; 2:113 - 6; http://dx.doi.org/10.1016/S1535-6108(02)00103-4; PMID: 12204531
   PubMed Web of Science ®Google Scholar
• Sun L, Hui AM, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S, Passaniti A, Menon J, Walling J, Bailey R, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 2006; 9:287 - 300; http://dx.doi.org/10.1016/j.ccr.2006.03.003; PMID: 16616334
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay A, Saddoughi SA, Song P, Sultan I, Ponnusamy S, Senkal CE, Snook CF, Arnold HK, Sears RC, Hannun YA, et al. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J 2009; 23:751 - 63; http://dx.doi.org/10.1096/fj.08-120550; PMID: 19028839
   PubMed Web of Science ®Google Scholar
• Ouellet V, Le Page C, Guyot MC, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM. SET complex in serous epithelial ovarian cancer. Int J Cancer 2006; 119:2119 - 26; http://dx.doi.org/10.1002/ijc.22054; PMID: 16823850
   PubMed Web of Science ®Google Scholar
• Ginos MA, Page GP, Michalowicz BS, Patel KJ, Volker SE, Pambuccian SE, Ondrey FG, Adams GL, Gaffney PM. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res 2004; 64:55 - 63; http://dx.doi.org/10.1158/0008-5472.CAN-03-2144; PMID: 14729608
   PubMed Web of Science ®Google Scholar
• Carlson SG, Eng E, Kim EG, Perlman EJ, Copeland TD, Ballermann BJ. Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms’ tumor. J Am Soc Nephrol 1998; 9:1873 - 80; PMID: 9773788
   PubMed Web of Science ®Google Scholar
• Korkola JE, Houldsworth J, Chadalavada RS, Olshen AB, Dobrzynski D, Reuter VE, Bosl GJ, Chaganti RS. Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res 2006; 66:820 - 7; http://dx.doi.org/10.1158/0008-5472.CAN-05-2445; PMID: 16424014
   PubMed Web of Science ®Google Scholar
• Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, Mao H, Chang JS, Galietta A, Uttam A, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005; 8:355 - 68; http://dx.doi.org/10.1016/j.ccr.2005.10.015; PMID: 16286244
   PubMed Web of Science ®Google Scholar
• Perrotti D, Neviani P. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Rev 2008; 27:159 - 68; http://dx.doi.org/10.1007/s10555-008-9119-x; PMID: 18213449
   PubMed Web of Science ®Google Scholar
• Adachi Y, Pavlakis GN, Copeland TD. Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia. J Biol Chem 1994; 269:2258 - 62; PMID: 8294483
   PubMed Web of Science ®Google Scholar
• Li M, Guo H, Damuni Z. Purification and characterization of two potent heat-stable protein inhibitors of protein phosphatase 2A from bovine kidney. Biochemistry 1995; 34:1988 - 96; http://dx.doi.org/10.1021/bi00006a020; PMID: 7531497
   PubMed Web of Science ®Google Scholar
• Li M, Makkinje A, Damuni Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem 1996; 271:11059 - 62; http://dx.doi.org/10.1074/jbc.271.19.11059; PMID: 8626647
   PubMed Web of Science ®Google Scholar
• Arnold HK, Sears RC. Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation. Mol Cell Biol 2006; 26:2832 - 44; http://dx.doi.org/10.1128/MCB.26.7.2832-2844.2006; PMID: 16537924
   PubMed Web of Science ®Google Scholar
• Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008; 14:152 - 60; http://dx.doi.org/10.1016/j.molmed.2008.02.001; PMID: 18329957
   PubMed Web of Science ®Google Scholar
• Canela N, Rodriguez-Vilarrupla A, Estanyol JM, Diaz C, Pujol MJ, Agell N, Bachs O. The SET protein regulates G2/M transition by modulating cyclin B-cyclin-dependent kinase 1 activity. J Biol Chem 2003; 278:1158 - 64; http://dx.doi.org/10.1074/jbc.M207497200; PMID: 12407107
   PubMed Web of Science ®Google Scholar
• Carujo S, Estanyol JM, Ejarque A, Agell N, Bachs O, Pujol MJ. Glyceraldehyde 3-phosphate dehydrogenase is a SET-binding protein and regulates cyclin B-cdk1 activity. Oncogene 2006; 25:4033 - 42; http://dx.doi.org/10.1038/sj.onc.1209433; PMID: 16474839
   PubMed Web of Science ®Google Scholar
• Compagnone NA, Zhang P, Vigne JL, Mellon SH. Novel role for the nuclear phosphoprotein SET in transcriptional activation of P450c17 and initiation of neurosteroidogenesis. Mol Endocrinol 2000; 14:875 - 88; http://dx.doi.org/10.1210/me.14.6.875; PMID: 10847589
   PubMed Web of Science ®Google Scholar
• Nagata K, Kawase H, Handa H, Yano K, Yamasaki M, Ishimi Y, Okuda A, Kikuchi A, Matsumoto K. Replication factor encoded by a putative oncogene, set, associated with myeloid leukemogenesis. Proc Natl Acad Sci U S A 1995; 92:4279 - 83; http://dx.doi.org/10.1073/pnas.92.10.4279; PMID: 7753797
   PubMed Web of Science ®Google Scholar
• Seo SB, McNamara P, Heo S, Turner A, Lane WS, Chakravarti D. Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein. Cell 2001; 104:119 - 30; http://dx.doi.org/10.1016/S0092-8674(01)00196-9; PMID: 11163245
   PubMed Web of Science ®Google Scholar
• Gamble MJ, Erdjument-Bromage H, Tempst P, Freedman LP, Fisher RP. The histone chaperone TAF-I/SET/INHAT is required for transcription in vitro of chromatin templates. Mol Cell Biol 2005; 25:797 - 807; http://dx.doi.org/10.1128/MCB.25.2.797-807.2005; PMID: 15632079
   PubMed Web of Science ®Google Scholar
• ten Klooster JP, Leeuwen Iv, Scheres N, Anthony EC, Hordijk PL. Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET. EMBO J 2007; 26:336 - 45; http://dx.doi.org/10.1038/sj.emboj.7601518; PMID: 17245428
   PubMed Web of Science ®Google Scholar
• Goc A, Abdalla M, Al-Azayzih A, Somanath PR. Rac1 activation driven by 14-3-3ζ dimerization promotes prostate cancer cell-matrix interactions, motility and transendothelial migration. PLoS One 2012; 7:e40594; http://dx.doi.org/10.1371/journal.pone.0040594; PMID: 22808202
   PubMedGoogle Scholar
• Arnold HK, Sears RC. A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins. Cancer Metastasis Rev 2008; 27:147 - 58; http://dx.doi.org/10.1007/s10555-008-9128-9; PMID: 18246411
   PubMed Web of Science ®Google Scholar
• Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell 2003; 112:659 - 72; http://dx.doi.org/10.1016/S0092-8674(03)00150-8; PMID: 12628186
   PubMed Web of Science ®Google Scholar
• Jensen SL, Wood DP Jr., Banks ER, Veron M, Lascu I, McRoberts JW, Rangnekar VM. Increased levels of nm23 H1/nucleoside diphosphate kinase A mRNA associated with adenocarcinoma of the prostate. World J Urol 1996; 14:Suppl 1 S21 - 5; http://dx.doi.org/10.1007/BF00182060; PMID: 8738406
   PubMedGoogle Scholar
• Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA, Vitek MP. Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene 2011; 30:2504 - 13; http://dx.doi.org/10.1038/onc.2010.622; PMID: 21297667
   PubMed Web of Science ®Google Scholar
• Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008; 9:139 - 50; http://dx.doi.org/10.1038/nrm2329; PMID: 18216770
   PubMed Web of Science ®Google Scholar
• Ogretmen B. Sphingolipids in cancer: regulation of pathogenesis and therapy. FEBS Lett 2006; 580:5467 - 76; http://dx.doi.org/10.1016/j.febslet.2006.08.052; PMID: 16970943
   PubMed Web of Science ®Google Scholar
• Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004; 4:604 - 16; http://dx.doi.org/10.1038/nrc1411; PMID: 15286740
   PubMed Web of Science ®Google Scholar
• Modrak DE, Gold DV, Goldenberg DM. Sphingolipid targets in cancer therapy. Mol Cancer Ther 2006; 5:200 - 8; http://dx.doi.org/10.1158/1535-7163.MCT-05-0420; PMID: 16505092
   PubMed Web of Science ®Google Scholar
• Riboni L, Campanella R, Bassi R, Villani R, Gaini SM, Martinelli-Boneschi F, Viani P, Tettamanti G. Ceramide levels are inversely associated with malignant progression of human glial tumors. Glia 2002; 39:105 - 13; http://dx.doi.org/10.1002/glia.10087; PMID: 12112362
   PubMed Web of Science ®Google Scholar
• Kimura K, Markowski M, Edsall LC, Spiegel S, Gelmann EP. Role of ceramide in mediating apoptosis of irradiated LNCaP prostate cancer cells. Cell Death Differ 2003; 10:240 - 8; http://dx.doi.org/10.1038/sj.cdd.4401145; PMID: 12700652
   PubMed Web of Science ®Google Scholar
• Koyanagi S, Kuga M, Soeda S, Hosoda Y, Yokomatsu T, Takechi H, Akiyama T, Shibuya S, Shimeno H. Elevation of de novo ceramide synthesis in tumor masses and the role of microsomal dihydroceramide synthase. Int J Cancer 2003; 105:1 - 6; http://dx.doi.org/10.1002/ijc.11024; PMID: 12672022
   PubMed Web of Science ®Google Scholar
• Rylova SN, Somova OG, Dyatlovitskaya EV. Comparative investigation of sphingoid bases and fatty acids in ceramides and sphingomyelins from human ovarian malignant tumors and normal ovary. Biochemistry (Mosc) 1998; 63:1057 - 60; PMID: 9795275
   PubMed Web of Science ®Google Scholar
• Eto M, Bennouna J, Hunter OC, Hershberger PA, Kanto T, Johnson CS, Lotze MT, Amoscato AA. C16 ceramide accumulates following androgen ablation in LNCaP prostate cancer cells. Prostate 2003; 57:66 - 79; http://dx.doi.org/10.1002/pros.10275; PMID: 12886525
   PubMed Web of Science ®Google Scholar
• Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005; 435:1262 - 6; http://dx.doi.org/10.1038/nature03672; PMID: 15988529
   PubMed Web of Science ®Google Scholar
• Watson JA, McKenna DJ, Maxwell P, Diamond J, Arthur K, McKelvey-Martin VJ, Hamilton PW. Hyperacetylation in prostate cancer induces cell cycle aberrations, chromatin reorganization and altered gene expression profiles. J Cell Mol Med 2010; 14:6B 1668 - 82; http://dx.doi.org/10.1111/j.1582-4934.2009.00835.x; PMID: 19583812
   PubMedGoogle Scholar
• Dart DA, Brooke GN, Sita-Lumsden A, Waxman J, Bevan CL. Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens. Oncogene 2012; 31:4588 - 98; http://dx.doi.org/10.1038/onc.2011.591; PMID: 22179832
   PubMed Web of Science ®Google Scholar
• Debret R, Brassart-Pasco S, Lorin J, Martoriati A, Deshorgue A, Maquart FX, Hornebeck W, Rahman I, Antonicelli F. Ceramide inhibition of MMP-2 expression and human cancer bronchial cell invasiveness involve decreased histone acetylation. Biochim Biophys Acta 2008; 1783:1718 - 27; http://dx.doi.org/10.1016/j.bbamcr.2008.06.001; PMID: 18598724
   PubMed Web of Science ®Google Scholar
• Zhu QY, Wang Z, Ji C, Cheng L, Yang YL, Ren J, Jin YH, Wang QJ, Gu XJ, Bi ZG, et al. C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivo. Cell Death Dis 2011; 2:e117; http://dx.doi.org/10.1038/cddis.2010.96; PMID: 21368888
   PubMed Web of Science ®Google Scholar
• Morgan TM, Koreckij TD, Corey E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 2009; 9:237 - 49; http://dx.doi.org/10.2174/156800909787580999; PMID: 19275762
   PubMed Web of Science ®Google Scholar
• Rudner J, Ruiner CE, Handrick R, Eibl HJ, Belka C, Jendrossek V. The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation. Radiat Oncol 2010; 5:108; http://dx.doi.org/10.1186/1748-717X-5-108; PMID: 21080918
   PubMed Web of Science ®Google Scholar
• Pandey AV, Mellon SH, Miller WL. Protein phosphatase 2A and phosphoprotein SET regulate androgen production by P450c17. J Biol Chem 2003; 278:2837 - 44; http://dx.doi.org/10.1074/jbc.M209527200; PMID: 12444089
   PubMed Web of Science ®Google Scholar
• Morad SA, Cabot MC. Ceramide-orchestrated signalling in cancer cells. Nat Rev Cancer 2013; 13:51 - 65; http://dx.doi.org/10.1038/nrc3398; PMID: 23235911
   PubMed Web of Science ®Google Scholar
• Morad SA, Levin JC, Shanmugavelandy SS, Kester M, Fabrias G, Bedia C, Cabot MC. Ceramide--antiestrogen nanoliposomal combinations--novel impact of hormonal therapy in hormone-insensitive breast cancer. Mol Cancer Ther 2012; 11:2352 - 61; http://dx.doi.org/10.1158/1535-7163.MCT-12-0594; PMID: 22962326
   PubMed Web of Science ®Google Scholar
• Stover TC, Sharma A, Robertson GP, Kester M. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res 2005; 11:3465 - 74; http://dx.doi.org/10.1158/1078-0432.CCR-04-1770; PMID: 15867249
   PubMed Web of Science ®Google Scholar
• Bielawski J, Szulc ZM, Hannun YA, Bielawska A. Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods 2006; 39:82 - 91; http://dx.doi.org/10.1016/j.ymeth.2006.05.004; PMID: 16828308
   PubMed Web of Science ®Google Scholar